| Trial ID: | L2409 |
| Source ID: | NCT06254274
|
| Associated Drug: |
Ray1225
|
| Title: |
A Study of RAY1225 in Participants With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
T2DM (Type 2 Diabetes Mellitus)
|
| Interventions: |
DRUG: RAY1225|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change From Baseline in Hemoglobin A1c (HbA1c), HbA1c is the glycosylated fraction of hemoglobin A., Baseline,Week 26 | Secondary: Percentage of Participants With HbA1c Target Value of <6.5%, Baseline,Week26|Percentage of Participants With HbA1c Target Value of <7%, Baseline,Week26|Percentage of Participants With HbA1c Target Value of <5.7%, Baseline,Week26|Change From Baseline in Fasting Serum Glucose, Baseline,Week26
|
| Sponsor/Collaborators: |
Sponsor: Guangdong Raynovent Biotech Co., Ltd
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
270
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2024-02-26
|
| Completion Date: |
2025-12-20
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-05
|
| Locations: |
Peking University People's Hospital, Beijing, Hebei, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06254274
|
